Views & Analysis Duchenne's disease: A New Hope Rare diseases, exceptional people: Filippo Buccella has battled for 25 years to improve care for children with
News Contrasting fortunes for Duchenne rivals, as PTC fails and S... Two rivals in the emerging Duchenne muscular dystrophy (DMD) therapy area have experienced contrasting fortunes this week.
News Marathon halts launch of Duchenne drug after price outcry Company says it will listen to concerns of patient advocates
Views & Analysis The biggest pharma stories of 2016 so far The top 10 pharma milestones of the year to date.
News Europe delays review of PTC's Duchenne drug Review of marketing authorisation delayed, new trial likely.
News NICE backs £220,000-a-year Duchenne drug following discount The National Health Service should fund PTC Therapeutics' Duchenne Muscular Dystrophy drug, Translarna (ataluren), NICE has said, after the company agreed a discount on the list price of £2
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
